How ALS2 processes silver from defibrillator pad electrolyte waste

Defibrillator pads are single-use medical consumables, but their spent gel and electrolyte can retain valuable silver from conductive layers. After clinical use, the pad is contaminated waste rather than ordinary rubbish. Recovery therefore has two linked aims: maintain safe handling and separate a small precious-metal concentration from a much larger mixture of organic gel, salts, adhesives and backing materials.

The residue is not a ready-to-melt feedstock. Pad construction, manufacturer and storage history affect whether silver occurs as particles, silver compounds or ions associated with the paste. Water content also changes the weight of a delivery. Any commercial assessment needs representative sampling and elemental analysis, followed by mass-balance calculations that account for silver in both the recoverable fraction and the discarded solids.

ALS2Project presents Ikoi S.p.A.’s acidless separation technology as a route to recovering precious metals without relying on bulk acid digestion. For defibrillator pad electrolyte waste, the technology offers a controlled way to capture silver-bearing material from a low-grade residue. Its relevance extends to compact precious-metal recovery plants serving electronic-waste and WEEE facilities, where similar separation principles can improve material recovery and reduce corrosive handling.

European Union Horizon 2020 support has helped frame ALS2 as a research and innovation programme with international ambition. Australia is a practical deployment market because hospital suppliers, biomedical-waste contractors and e-waste recyclers already handle substantial volumes of contaminated equipment. The opportunity is to turn a specialised waste stream into a traceable silver feed while meeting stringent clinical-waste, transport and environmental obligations.

Why defibrillator pad residue needs a dedicated route

Defibrillator pads commonly combine a flexible backing, conductive ink or fabric, an adhesive layer and a conductive gel. Depending on the model, silver may be present as elemental silver in the conductive layer or as silver chloride after contact with chloride-containing paste. The electrolyte also contains salts and water, while clinical use can introduce biological contamination. These variables make chemical speciation and sample preparation central to any silver-extraction claim.

A dedicated route starts with segregation at the point of use. Used pads should remain in approved packaging and move through the biomedical-waste chain, with staff following the hospital’s infection-control and waste procedures. At the recovery plant, an operator records the source, weight and batch, then removes non-processable items under a written method. Representative samples establish silver grade, moisture and the fraction held in the solid backing versus the liquid or gel phase.

How ALS2 prepares the silver-bearing waste

Preparation turns the collected pads into a consistent feed. The gel is released from the flexible backing, cables are separated, and the silver-bearing fraction is transferred to a closed vessel. Depending on the pad design, the process may combine, screen or wash this material. The aim is to obtain a homogeneous slurry without sending plastics, adhesive or metallic connectors into the separation unit. Contamination control matters because chlorine and other halogens can influence silver chemistry.

Each production batch should be balanced against laboratory assay results rather than a nominal silver percentage. ALS2 can then work from a defined feed composition, with reagent addition and separation conditions adjusted for the actual residue. Measuring silver in every outgoing stream closes the mass balance and identifies where losses occur. This approach also prevents high-grade batches from being masked by wet or low-grade material, which is essential when determining whether a compact plant can operate economically.

The acidless separation sequence

At process level, the ALS2 route is a sequence of conditioning, selective separation and concentration. The incoming slurry is treated under controlled conditions so that the silver-bearing phase can be separated from bulk gel and inert solids. Liquid-solid separation steps then isolate a silver-containing stream from the remaining residue, and polishing stages reduce unwanted impurities. The exact chemistry, operating windows and equipment configuration must be established through ALS2 testing for the specific pad waste.

The acidless approach avoids using concentrated mineral acid to digest the whole feed. That can reduce corrosive handling, simplify chemical control and protect downstream equipment, although other reagents, effluent treatment and operator safeguards remain necessary. This is not the random redistribution seen in a blackjack shuffle machine: ALS2 depends on chemical affinity, phase behaviour and recorded process conditions. Its output at this stage is normally a silver-rich intermediate that still requires verification and final refining.

Recovering and verifying the silver product

The silver-rich fraction moves to a controlled finishing stage, where the required purity and form are defined. Depending on the chosen route and customer specification, further precipitation, reduction, electrolysis or fusion may be used to produce metal, concentrate or another refinery input. ALS2’s separation work should not be confused with final bullion production. Every batch needs fire assay or an accredited analytical laboratory check before its silver value can be established and the material sold.

Treating the remaining liquid and solid fractions completes the process design. Water may be reused after quality checks, while reagents can be recovered or purchased in a controlled loop if the chemistry and local regulations permit. The environmental case is strongest when avoided acid use, recovered silver and reduced hazardous volume outweigh the impacts of reagent manufacture, energy demand and transport. A complete life-cycle assessment is more credible than a simple claim that the waste disappears.

Compact plants for distributed recovery

A compact precious-metal recovery plant can be positioned near a biomedical-waste contractor or an established e-waste and WEEE processing hub. That shortens the chain from generator to separation equipment and keeps pad handling within an already controlled waste system. Defibrillator pads alone may produce modest feed volumes, so co-processing them with suitable silver-bearing electronic-waste fractions can improve plant utilisation. Modular equipment also allows capacity to be expanded as validated streams are added.

Compact does not mean low-control. The installation still needs sealed transfer, bunding, ventilation appropriate to the reagents, filtration, spill containment, dust management where solids are handled, and routine equipment maintenance. Remote monitoring can record reagent dosing, flow, temperature and pressure, while laboratory assays provide the final quality check. For Australian sites, these controls should be incorporated into the facility design before clinical or e-waste material arrives.

Fit with Australian waste and market conditions

Large hospital networks in Sydney, Melbourne and Brisbane are obvious source partners because they generate regular streams of single-use medical consumables. Their biomedical-waste contractors already manage sealed collection, licensed transport and treatment. Used defibrillator pads belong in that clinical chain, while devices and batteries removed from them may follow separate electrical- or battery-safety pathways. Keeping these streams distinct prevents contamination of a valuable silver feed with unrelated metals.

Australian disposal rules vary by state and territory, and a local e-waste stewardship scheme may not accept medical consumables simply because they contain electronics. Project proponents should confirm classification with the relevant environment and public-health authorities, and the waste contractor should verify manufacturer handling instructions and device return arrangements. The Australian Therapeutic Goods Administration regulates relevant medical devices and sponsors, but that role does not replace local waste-disposal duties or a documented chain of custody.

If a pilot module, reagent or specialist service is imported, customs planning begins before shipment. The Australian Customs Service may require an import declaration, correct tariff classification and supporting documents; classified chemicals can also require dangerous-goods information, while waste movements across state borders can trigger separate controls. Once recovered silver is verified, Australian refiners, bullion dealers and industrial buyers provide potential destinations, with transaction value affected by assay, purity and prevailing silver prices in Australian dollars.

Build a practical silver recovery pathway

A sound pilot starts with a defined waste stream, representative samples and a measured silver balance. Operators can then establish pad-to-residue yield, identify contaminants, test separation performance and calculate chemical, energy, labour and logistics costs. The business case should compare the compact ALS2 plant with secure disposal and with conventional refining routes, while accounting for clinical-waste charges, carbon impacts and the value of recovered metal. Site-specific data are essential because hospital contracts, transport distances and feed composition vary widely.

Ikoi S.p.A. and the ALS2Project team can support discussions with hospitals, waste contractors, recyclers and investors on a structured evaluation. The immediate action is to secure a representative sample, map the collection route and confirm the Australian regulatory pathway with qualified local partners. A measured pilot then creates the technical, environmental and commercial evidence needed to move from isolated pad waste towards a broader precious-metal recovery system for electronic and clinical waste streams.